UroGen Pharma(URGN) - 2024 Q2 - Quarterly Results

Exhibit 99.1 UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights • Potential for an FDA decision as early as the first quarter of 2025, assuming priority review • UGN-102 Phase 3 ENVISION trial demonstrated an unprecedented 82.3% Duration of Response at 12 Months by Kaplan-Meier analysis in LG-IR-NMIBC patients who achieved a complete response at three months • Ended Q2 2024 with $241.3 million in cash, cash equivalents ...